US Stock MarketDetailed Quotes

ANIX Anixa Biosciences

Watchlist
  • 2.790
  • +0.040+1.45%
Close Apr 30 16:00 ET
  • 2.840
  • +0.050+1.79%
Post 20:01 ET
89.83MMarket Cap-7.15P/E (TTM)

Anixa Biosciences Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q1)Jan 31, 2025
(FY)Oct 31, 2024
(Q4)Oct 31, 2024
(Q3)Jul 31, 2024
(Q2)Apr 30, 2024
(Q1)Jan 31, 2024
(FY)Oct 31, 2023
(Q4)Oct 31, 2023
(Q3)Jul 31, 2023
(Q2)Apr 30, 2023
Total revenue
0
0
0
0
0
0
210K
0
0
210K
Operating revenue
--0
--0
--0
--0
--0
--0
--210K
--0
--0
--210K
Cost of revenue
0
0
0
0
161K
0
0
161K
Gross profit
0
0
0
0
49K
0
0
49K
Operating expense
-6.18%3.39M
25.05%13.83M
3.67%3.16M
26.30%3.59M
32.89%3.47M
41.20%3.61M
-20.29%11.06M
-15.46%3.05M
1.68%2.84M
-27.31%2.61M
Selling and administrative expenses
-18.85%1.83M
18.18%7.44M
17.48%1.69M
-5.07%1.67M
13.04%1.82M
51.88%2.26M
-12.28%6.29M
-25.36%1.44M
29.88%1.76M
-13.11%1.61M
-General and administrative expense
-18.85%1.83M
18.18%7.44M
17.48%1.69M
-5.07%1.67M
13.04%1.82M
51.88%2.26M
-12.28%6.29M
-25.36%1.44M
29.88%1.76M
-13.11%1.61M
Research and development costs
15.05%1.55M
34.12%6.4M
-8.61%1.48M
76.93%1.93M
64.93%1.65M
26.31%1.35M
-28.85%4.77M
-4.15%1.62M
-24.71%1.09M
-42.48%998K
Operating profit
6.18%-3.39M
-25.61%-13.83M
-3.67%-3.16M
-26.30%-3.59M
-35.43%-3.47M
-41.20%-3.61M
20.64%-11.01M
15.46%-3.05M
-1.68%-2.84M
28.67%-2.56M
Net non-operating interest income expense
-45.77%173K
4.81%1.13M
-24.24%250K
-6.42%277K
13.44%287K
57.92%319K
939.42%1.08M
312.50%330K
1,245.45%296K
25,200.00%253K
Non-operating interest income
-45.77%173K
4.81%1.13M
-24.24%250K
-6.42%277K
13.44%287K
57.92%319K
939.42%1.08M
312.50%330K
1,245.45%296K
25,200.00%253K
Other net income (expense)
Income before tax
2.34%-3.21M
-27.88%-12.7M
-7.06%-2.91M
-30.10%-3.32M
-37.84%-3.18M
-39.76%-3.29M
27.89%-9.93M
22.90%-2.72M
8.18%-2.55M
35.70%-2.31M
Income tax
Net income
2.34%-3.21M
-27.88%-12.7M
-7.06%-2.91M
-30.10%-3.32M
-37.84%-3.18M
-39.76%-3.29M
27.89%-9.93M
22.90%-2.72M
8.18%-2.55M
35.70%-2.31M
Net income continuous Operations
2.34%-3.21M
-27.88%-12.7M
-7.06%-2.91M
-30.10%-3.32M
-37.84%-3.18M
-39.76%-3.29M
27.89%-9.93M
22.90%-2.72M
8.18%-2.55M
35.70%-2.31M
Minority interest income
17.14%-29K
-21.01%-144K
3.23%-30K
-2.70%-38K
-115.79%-41K
-9.38%-35K
32.39%-119K
41.51%-31K
-27.59%-37K
56.82%-19K
Net income attributable to the parent company
2.18%-3.18M
-27.96%-12.55M
-7.17%-2.88M
-30.51%-3.28M
-37.19%-3.14M
-40.18%-3.26M
27.83%-9.81M
22.61%-2.69M
8.56%-2.51M
35.44%-2.29M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
2.18%-3.18M
-27.96%-12.55M
-7.17%-2.88M
-30.51%-3.28M
-37.19%-3.14M
-40.18%-3.26M
27.83%-9.81M
22.61%-2.69M
8.56%-2.51M
35.44%-2.29M
Basic earnings per share
0.00%-0.1
-21.88%-0.39
0.00%-0.09
-25.00%-0.1
-42.86%-0.1
-25.00%-0.1
28.89%-0.32
25.00%-0.09
11.11%-0.08
41.67%-0.07
Diluted earnings per share
0.00%-0.1
-21.88%-0.39
0.00%-0.09
-25.00%-0.1
-42.86%-0.1
-25.00%-0.1
28.89%-0.32
25.00%-0.09
11.11%-0.08
41.67%-0.07
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Audit Opinions
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
(Q1)Jan 31, 2025(FY)Oct 31, 2024(Q4)Oct 31, 2024(Q3)Jul 31, 2024(Q2)Apr 30, 2024(Q1)Jan 31, 2024(FY)Oct 31, 2023(Q4)Oct 31, 2023(Q3)Jul 31, 2023(Q2)Apr 30, 2023
Total revenue 000000210K00210K
Operating revenue --0--0--0--0--0--0--210K--0--0--210K
Cost of revenue 0000161K00161K
Gross profit 000049K0049K
Operating expense -6.18%3.39M25.05%13.83M3.67%3.16M26.30%3.59M32.89%3.47M41.20%3.61M-20.29%11.06M-15.46%3.05M1.68%2.84M-27.31%2.61M
Selling and administrative expenses -18.85%1.83M18.18%7.44M17.48%1.69M-5.07%1.67M13.04%1.82M51.88%2.26M-12.28%6.29M-25.36%1.44M29.88%1.76M-13.11%1.61M
-General and administrative expense -18.85%1.83M18.18%7.44M17.48%1.69M-5.07%1.67M13.04%1.82M51.88%2.26M-12.28%6.29M-25.36%1.44M29.88%1.76M-13.11%1.61M
Research and development costs 15.05%1.55M34.12%6.4M-8.61%1.48M76.93%1.93M64.93%1.65M26.31%1.35M-28.85%4.77M-4.15%1.62M-24.71%1.09M-42.48%998K
Operating profit 6.18%-3.39M-25.61%-13.83M-3.67%-3.16M-26.30%-3.59M-35.43%-3.47M-41.20%-3.61M20.64%-11.01M15.46%-3.05M-1.68%-2.84M28.67%-2.56M
Net non-operating interest income expense -45.77%173K4.81%1.13M-24.24%250K-6.42%277K13.44%287K57.92%319K939.42%1.08M312.50%330K1,245.45%296K25,200.00%253K
Non-operating interest income -45.77%173K4.81%1.13M-24.24%250K-6.42%277K13.44%287K57.92%319K939.42%1.08M312.50%330K1,245.45%296K25,200.00%253K
Other net income (expense)
Income before tax 2.34%-3.21M-27.88%-12.7M-7.06%-2.91M-30.10%-3.32M-37.84%-3.18M-39.76%-3.29M27.89%-9.93M22.90%-2.72M8.18%-2.55M35.70%-2.31M
Income tax
Net income 2.34%-3.21M-27.88%-12.7M-7.06%-2.91M-30.10%-3.32M-37.84%-3.18M-39.76%-3.29M27.89%-9.93M22.90%-2.72M8.18%-2.55M35.70%-2.31M
Net income continuous Operations 2.34%-3.21M-27.88%-12.7M-7.06%-2.91M-30.10%-3.32M-37.84%-3.18M-39.76%-3.29M27.89%-9.93M22.90%-2.72M8.18%-2.55M35.70%-2.31M
Minority interest income 17.14%-29K-21.01%-144K3.23%-30K-2.70%-38K-115.79%-41K-9.38%-35K32.39%-119K41.51%-31K-27.59%-37K56.82%-19K
Net income attributable to the parent company 2.18%-3.18M-27.96%-12.55M-7.17%-2.88M-30.51%-3.28M-37.19%-3.14M-40.18%-3.26M27.83%-9.81M22.61%-2.69M8.56%-2.51M35.44%-2.29M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 2.18%-3.18M-27.96%-12.55M-7.17%-2.88M-30.51%-3.28M-37.19%-3.14M-40.18%-3.26M27.83%-9.81M22.61%-2.69M8.56%-2.51M35.44%-2.29M
Basic earnings per share 0.00%-0.1-21.88%-0.390.00%-0.09-25.00%-0.1-42.86%-0.1-25.00%-0.128.89%-0.3225.00%-0.0911.11%-0.0841.67%-0.07
Diluted earnings per share 0.00%-0.1-21.88%-0.390.00%-0.09-25.00%-0.1-42.86%-0.1-25.00%-0.128.89%-0.3225.00%-0.0911.11%-0.0841.67%-0.07
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Audit Opinions --Unqualified Opinion--------Unqualified Opinion------

Market Insights

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
CG MED EQUIP.
838810
+29.98%
BEOKA
870199
+29.96%
Shenzhen Bromake New Material
301387
+20.01%
4
Zhejiang Hongchang Electrical Technology
301008
+20.00%
5
Wuhan Lincontrol Automotive Electronics Co., Ltd.
688667
+20.00%
Log In for the Full List
Unlock Now

Investment Course

Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.

Discussing

Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
MicroStrategy Q4 2024 earnings conference call

Earnings Season Underway

Earnings season is here. What to know?